Compugen (NASDAQ:CGEN) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a report released on Thursday.

Separately, Truist Financial dropped their price target on shares of Compugen from $5.00 to $4.00 and set a buy rating for the company in a research report on Tuesday, May 21st.

Compugen Stock Performance

Shares of CGEN stock opened at $1.68 on Thursday. The stock has a market cap of $145.52 million, a price-to-earnings ratio of -8.84 and a beta of 2.71. Compugen has a 52-week low of $0.53 and a 52-week high of $3.03. The firm’s 50-day moving average is $2.05 and its 200-day moving average is $2.14.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Monday, May 20th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. The company had revenue of $2.56 million during the quarter, compared to analyst estimates of $2.79 million. Sell-side analysts predict that Compugen will post 0.05 EPS for the current fiscal year.

Institutional Trading of Compugen

A hedge fund recently bought a new stake in Compugen stock. Heron Bay Capital Management acquired a new stake in Compugen Ltd. (NASDAQ:CGEN) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 12,547 shares of the biotechnology company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.